B+
Overall grade
B+
Financial quality
The sleeper story is Fetal Focus expansion to 20 genes - they've quietly built validation data from 1,700 high-risk pregnancies and can roll this through their entire existing customer base with zero incremental sales cost. The obvious headline is another Signatera growth record, but the real story is their shift from growth to efficiency optimization without explaining why. The binding constraint isn't demand - it's their deliberate choice to stop hiring reps despite record new patient starts. Chapman said 'we aren't planning any big commercial expansions anytime soon' after beating their own growth records. Most revealing quote: 'We estimate the growth in Signatera ASP this quarter was driven primarily by the success we had in the spring and fall working with health plans in these states to cover Signatera.' My view changes if the $60M one-time expenses prove to be recurring operational costs masked as non-recurring items.
The 30-second version
- SLEEPER: Fetal Focus expansion to 20 genes is the stealth growth engine everyone's missing
- Signatera growth beat was real, but the guidance framework just got more conservative
- OpEx discipline is masking a $60M one-time problem that's getting buried
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Revenue | $547M (+32% YoY) | $592M (+35% YoY) |
| Gross Margin | 63.4% | 64.9% |
| Signatera Units | +20,000 sequential | +21,500 sequential |
| Signatera ASP | $1,175 | $1,200 |
| DSO | 57 days | 49 days |
| Revenue True-ups | $45M | $55M |
| R&D Investment | Not specified | Increased for MolDx submissions |
| Free Cash Flow Guide | Not specified Q2 | $100M for full year |
Accountability tracked
7 new promises made3 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →